Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEP-ENHANCE trial of adjunctive cannabidiol in first-episode psychosis
NL-OMON61333Phase 3Not yet recruiting
- Sponsor
- University of Oxford
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in psychosis, schizophrenia, schizoaffective disorder and 1 more, sponsored by University of Oxford. Primary endpoint: Change in total PANSS score at 6 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
cannabidiol
03
Conditions
psychosisschizophreniaschizoaffective disorderschizophreniform disorder
Beyond the preview
Go deeper on NL-OMON61333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61333.